CNS Pharmaceuticals (CNSP) Corporate Media Kit

CNS pharmaceuticals 4 Investment Highlights. • Focusing on unmet need as glioblastoma multiforme (GBM) is the most common and aggressive form of brain cancer - IND approved on December 16, 2020 - Orphan drug designation for malignant gliomas received in June 2020 - Upside in additional cancer types • Lead drug candidate is the first anthracycline shown to cross the blood-brain barrier in adults - Positive Phase 1 results - Potentially Pivotal Phase 2 clinical trial expected to commence in Q1 2021 • Clinical development partnership with WPD Pharmaceuticals in Poland enhances ability to advance drug in the clinic - R&D commitments for commercial rights in Eastern Europe and Central Asia - Received $6 million in grants to perform 2 clinical studies - First-ever Phase 1 pediatric study to be performed • Pipeline includes novel class of potential DNA binding therapeutics, shown to be 500x more potent than classic DNA binders in animal testing • Appointed Dr. Patrick Wen to the Scientific Advisory Board: Director of the Center for Neuro-Oncology at Dana Farber Cancer Institute, Professor of Neurology at Harvard Medical School Board of Directors & past President of the Society for Neuro-Oncology. • Development agreement with WPD for an anti-viral portfolio with potential COVID-19 applications